PTN - Palatin Technologies Inc.

PTN Stock Chart

PTN Profile

Palatin Technologies, Inc., headquartered in Cranbury, New Jersey, is a pioneering biopharmaceutical firm focused on developing highly targeted receptor-specific therapeutics aimed at treating diverse medical conditions within the United States. Established in 1986, Palatin is known for its innovative approach to addressing unmet medical needs.

At the forefront of its product portfolio is Vyleesi, the company's lead product and a melanocortin receptor (MCr) agonist designed specifically for premenopausal women diagnosed with hypoactive sexual desire disorder. This groundbreaking therapy underscores Palatin's commitment to advancing treatments in women's health.

Palatin Technologies also boasts a robust pipeline that includes PL8177, an oral selective MC1r agonist peptide, which has successfully completted Phase I clinical trials targeting inflammatory bowel diseases. Additionally, the company is advancing PL9643, a peptide melanocortin agonist effective across multiple MCrs, including applications for treating inflammatory ocular conditions such as dry eye disease and diabetic retinopathy.

Furthermore, Palatin Technologies is actively developing PL3994, a peptide mimetic molecule designed with amino acid properties, and exploring L8177, an oral peptide formulation currently in Phase 2 clinical trials for the treatment of ulcerative colitis. These initiatives highlight Palatin's dedication to leveraging scientific innovation to improve patient outcomes across a spectrum of challenging medical conditions.

PTN Revenue Chart

PTN Earnings

Analyst Ratings